


## PHARMACEUTICAL 2019



## Neoleukin Therapeutics Inc. Rank 54 of 363





## PHARMACEUTICAL 2019





## Neoleukin Therapeutics Inc. Rank 54 of 363

The relative strengths and weaknesses of Neoleukin Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neoleukin Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 74% points. The greatest weakness of Neoleukin Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 226%, being 190% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	77,165
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,627
Liabilities, Non-Current	319
Other Assets	53
Other Compr. Net Income	70
Other Expenses	0
Other Liabilities	0
Other Net Income	1,039
Other Revenues	25,000
Property and Equipment	400
Research and Development	41,789
Selling, General and Administrative Expense	15,835

Output Variable	Value in 1000 USD
Assets	77,618
Liabilities	4,946
Expenses	57,624
Revenues	25,000
Stockholders Equity	72,672
Net Income	-31,585
Comprehensive Net Income	-31,550
Economic Capital Ratio	226%

